What is the Gufic Biosciences Ltd share price today?

The share price of NSE:GUFICBIO-EQ on 07 Sep 2026 (as of 10:59:24 IST) is ₹447.85.

What is the NSE:GUFICBIO-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:GUFICBIO-EQ 52 week high low range shows a high of ₹467.80 and a low of ₹268.00.

What is the Gufic Biosciences Ltd market cap?

As on 07 Sep 2026, Gufic Biosciences Ltd market cap is ₹4466.58 Cr.

What is the shareholding pattern of Gufic Biosciences Ltd Stock?

The shareholding pattern of Gufic Biosciences Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 72.50% Foreign Institutional Investors (FII): 0.47% Domestic Institutional Investors (DII): 0.24% Mutual Funds: 3.43% Retail & Others: 23.36% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Gufic Biosciences Ltd?

The Price-to-Earnings (PE) ratio of Gufic Biosciences Ltd is 60.81, and the Price-to-Book (PB) ratio is 4.14, as on 07 Sep 2026.

Gufic Biosciences Share Price

422.00-15.45 (-3.53%)

+13.56% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-3.53%

1 Week

-3.21%

1 Month

+2.02%

3 Month

+16.69%

6 Month

+50.47%

YTD

+25.60%

1 Year

+13.56%

5 Year

+112.06%

10 Year

+1006.16%

Max

+1276.84%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

417.60

395.05

359.15

273.00

268.00

High

441.95

449.00

467.80

About

Gufic Biosciences Limited is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognised Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

GUFICBIONSE

LTP

1W Low

1W High

Market cap (₹)

1849.9+12.6 (0.69%)

1832.20

1891.50

4,47,476Cr

9602+227 (2.42%)

9312.50

9740

2,54,764Cr

4928.5+88.5 (1.83%)

4848.50

5010

1,89,423Cr

1180.3+20.3 (1.75%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2026.2+72.2 (3.69%)

1963.80

2055.30

1,09,943Cr

2500+199.3 (8.66%)

2303

2504.30

1,01,712Cr

1200.4+15.4 (1.30%)

1185

1222

1,01,005Cr

1716-18 (-1.04%)

1689.30

1740

99,253Cr

2100.7+17.7 (0.85%)

2080

2135

96,031Cr

424-12 (-2.75%)

417.60

449

4,381Cr

Gufic Biosciences Share Price

422.00-15.45 (-3.53%)

+13.56% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years-

Last year15%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year-8%

Stock Price CAGR

10 years27%

5 years17%

3 years15%

1 year15%

Return on Equity

10 years13%

5 years13%

3 years13%

Last year10%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	-	15%
-	-	-	-8%
27%	17%	15%	15%
13%	13%	13%	10%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

GUFICBIO

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.9	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,602	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,928.5	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180.3	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,500	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,716	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,100.7	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
424	₹4381 Cr	59.65	2.23	10.4	₹64 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024
—	—	—
₹10 Cr	₹10 Cr	₹10 Cr
₹0	₹10 L	₹0
₹655 Cr	₹591 Cr	₹523 Cr
₹655 Cr	₹591 Cr	₹523 Cr
₹665 Cr	₹601 Cr	₹533 Cr
₹4 L	₹0	₹0
₹105 Cr	₹131 Cr	₹154 Cr
₹17 Cr	₹8 Cr	₹2 Cr
₹20 Cr	₹25 Cr	₹17 Cr
₹18 Cr	₹17 Cr	₹15 Cr
₹160 Cr	₹181 Cr	₹188 Cr
—	—	—
₹199 Cr	₹159 Cr	₹166 Cr
₹58 Cr	₹70 Cr	₹56 Cr
₹254 Cr	₹154 Cr	₹142 Cr
₹6 Cr	₹4 Cr	₹7 Cr
₹518 Cr	₹388 Cr	₹372 Cr
₹1342 Cr	₹1169 Cr	₹1093 Cr
₹12 Cr	₹6 Cr	₹7 Cr
₹385 Cr	₹310 Cr	₹317 Cr
—	—	—
₹630 Cr	₹614 Cr	₹246 Cr
₹139 Cr	₹108 Cr	₹87 Cr
₹491 Cr	₹506 Cr	₹159 Cr
₹22 Cr	₹22 Cr	₹307 Cr
₹2 Cr	₹2 Cr	₹2 Cr
₹2 Cr	₹2 Cr	₹2 Cr
₹24 Cr	₹13 Cr	₹23 Cr
₹2 Cr	₹2 Cr	₹1 Cr
₹540 Cr	₹545 Cr	₹492 Cr
—	—	—
₹324 Cr	₹217 Cr	₹200 Cr
₹297 Cr	₹315 Cr	₹330 Cr
₹76 Cr	₹29 Cr	₹13 Cr
₹2 Cr	₹2 Cr	₹4 Cr
₹102 Cr	₹63 Cr	₹53 Cr
₹802 Cr	₹625 Cr	₹600 Cr
₹284 Cr	₹237 Cr	₹228 Cr
₹1342 Cr	₹1169 Cr	₹1093 Cr
₹66	₹60	₹53
₹66	₹60	₹53

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024
₹87 Cr	₹94 Cr	₹116 Cr
₹65 Cr	₹44 Cr	₹34 Cr
-₹95 Cr	₹7 Cr	-₹130 Cr
₹57 Cr	₹145 Cr	₹20 Cr
₹45 Cr	₹123 Cr	-₹7 Cr
-₹31 Cr	-₹71 Cr	-₹102 Cr
₹32 Cr	-₹37 Cr	₹82 Cr
₹46 Cr	₹15 Cr	-₹27 Cr
₹16 Cr	₹1 Cr	₹29 Cr
₹62 Cr	₹16 Cr	₹1 Cr

Fundamental Ratios

Consolidated

Standalone

Gufic Biosciences Share Price

422.00-15.45 (-3.53%)

+13.56% past 1 Year

Shareholding summary

Promoters

72.5%

FII

0.47%

DII

0.24%

3.43%

Others

23.36%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
72.50%	72.50%	72.50%	72.50%	72.52%	72.51%
0.47%	0.42%	0.44%	0.33%	0.32%	0.31%
0.24%	0.20%	0.21%	0.18%	0.00%	0.00%
3.43%	3.63%	3.53%	3.48%	3.38%	3.39%
23.36%	23.25%	23.32%	23.51%	23.78%	23.79%

Bulk & block deals

Name

Graviton Research Capital Llp

Financial Investors Trust A/C Grandeur Peak Global Opportunities Fund

Graviton Research Capital Llp

Sbi Mutual Fund

Parth Infin Brokers Pvt. Ltd.

Parth Infin Brokers Pvt Ltd

Sbi Mutual Fund

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
30 Nov 2023	Purchase	19.38 Cr	₹329.69	5.88 L	Bulk	0.586131	NSE
30 Nov 2023	Sell	19.38 Cr	₹329.72	5.88 L	Bulk	0.586131	NSE
12 Aug 2021	Purchase	10.29 Cr	₹205.89	5 L	Bulk	0.498591	NSE
12 May 2021	Purchase	8.75 Cr	₹190.06	4.60 L	Bulk	0.458829	NSE
12 May 2021	Sell	8.74 Cr	₹189.94	4.60 L	Bulk	0.458829	NSE
18 May 2017	Purchase	19.23 Cr	₹60.10	32 L	Bulk	3.190985	BSE
18 May 2017	Purchase	13.04 Cr	₹60.10	21.70 L	Bulk	2.163887	BSE
18 May 2017	Purchase	10.11 Cr	₹72.67	13.91 L	Bulk	1.38739	BSE
18 May 2017	Purchase	5.13 Cr	₹76.54	6.71 L	Bulk	0.668683	NSE
18 May 2017	Purchase	3 Cr	₹60.10	5 L	Bulk	0.498591	BSE

Insider trading & SAST

Client name

Jayesh P Choksi & Pacs

Jayesh Choksi

Jayesh P Choksi & Others (Revised)

Vipul J Choksi & Pacs

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
03 Jun 2022	Promoter	Disposal	0.48	25.47	0	—	4.68 L	02 Jun 2022	Market	2,46,90,829	SAST	29(2)	—
03 Jun 2022	Promoter & Director	Disposal	0.018567	25.47	39.68 L	₹220.43	18 K	02 Jun 2022	Market Sale	2,46,90,829	Insider Trading	—	Equity Shares
03 Jun 2022	Promoter & Director	Disposal	0.464181	25.49	9.79 Cr	₹217.65	4.50 L	02 Jun 2022	Market Sale	2,47,08,829	Insider Trading	—	Equity Shares
27 Sep 2021	Promoter	Acquisition	19.72	75.48	0	—	1.91 Cr	04 Jun 2021	Scheme Of Amalgamation	7,31,76,151	SAST	29(2)	—
25 Sep 2021	Promoter	Acquisition	19.72	75.48	0	—	1.91 Cr	04 Jun 2021	Scheme Of Amalgamation	7,31,76,151	SAST	29(2)	—

Gufic Biosciences Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Gufic Biosciences Share Price

Gufic Biosciences Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Gufic Biosciences Share Price

Gufic Biosciences Share Price

Oscillators

Moving averages

Gufic Biosciences Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Gufic Biosciences Share Price

Corporate Actions

Company details

Gufic Biosciences Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Gufic Biosciences Share Price

News

Gufic Biosciences rules out greenfield capex, limits spend to replacement needs

Gufic Biosciences maintains gross debt near Rs 400 crores for growth needs

Gufic Biosciences shares guidance for EBITDA margin expansion through FY2030

Gufic Biosciences projects steady annual improvement in gross margin profile

Gufic Biosciences issues revenue growth guidance indicating stronger FY performance outlook

Gufic Biosciences surges on getting nod to make further investment in Saraswat Co-operative Bank

Gufic Biosciences posts strong Q4 EBITDA growth with improved margins YoY

Gufic Biosciences Q4 FY earnings show strong profit and revenue growth

Gufic Biosciences gets nod to make further investment in Saraswat Co-operative Bank

Gufic Biosciences reports Profit after tax of 20.58 Crores, in the March 2026 quarter

Gufic Biosciences makes investment of $50,000 in Selvax

Gufic Biosciences invests USD 50,000 in Selvax Pty Ltd by acquiring 378,350 shares.

Gufic Biosciences reports Profit after tax of 15.56 Crores, in the December 2025 quarter

Gufic Biosciences Q3FY26 Earnings: Revenue Up 11%, EBITDA Growth 3.63%, PAT Down 19%.

Gufic BioSciences Q3FY26 Results: Revenue Up 11% YoY, Net Profit Down 19% YoY.

Gufic Biosciences targets strong export-led growth in injectables; Indore facility operational by FY26

Gufic Biosciences reports Profit after tax of 14.93 Crores, in the September 2025 quarter

Gufic Biosciences Q2 FY25 EBITDA declines YoY; EBITDA margin contracts on lower revenue.

Gufic Biosciences Q2 Net Profit and Revenue Update

Gufic Biosciences gains on making investment in Gufic Ireland

Gufic Biosciences Ltd Share Price Today

Gufic Biosciences Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator